Patent News: Breaking Patent News, Comments and Articles. - Page: 4

Point of Care Diagnostics Market Research Report Submitted by Transparency Market Research

Albany, NY, May 15, 2013 --(PR.com)-- Point of care (POC) diagnostics comprises of diagnostic tests that are performed at the patient site. POC diagnostics provides fast results which in turn help in faster patient management. The present POC diagnostics market already sports a number of products with several new products in the development stage. The worldwide diagnostics market is experiencing...

Nanosphere to Present at UBS Global Healthcare Conference

NORTHBROOK, IL -- (Marketwired) -- 05/15/13 -- Nanosphere, Inc., (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that an overview of the company's business and commercial strategy will be given by Nanosphere's President and Chief Executive Officer Michael McGarrity at the UBS Global Healthcare Conference, being held at t...

DARA Reports First Quarter 2013 Financial Results and Operational Highlights

RALEIGH, NC--(Marketwired - May 15, 2013) - DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today its financial results for the first quarter ended March 31, 2013. The Company also summarized the first quarter 2013 operational highlights, its recent developments, and provided a commercial and developmen...

Biologix Hair Inc. Appoints Dr. Michael Stocker Director and Chief Executive Officer; J. Gregory Wilson Appointed Chief Financial Officer

TORONTO, ONTARIO -- (Marketwired) -- 05/15/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) has appointed Dr. Michael Stocker as Chief Executive Officer and to the Company's Board of Directors and J. Gregory Wilson as Chief Financial Officer. Outgoing CEO, Ron Holland, will continue to serve as Chairman of the Board of Directors. Biologix Chairman Ron Holland stated: "Over the past weeks and...

BIOLASE Awarded Two New Patents

IRVINE, CA -- (Marketwired) -- 05/15/13 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Patent and Trademark Office ("USPTO") has awarded BIOLASE® two new patents. Patent 8,439,904 titled "Tapered Fused Waveguide for Teeth Whitening" is related to providing specially designed waveguide delivery systems which can b...

Titan Pharmaceuticals Announces First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/15/13 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the first quarter ended March 31, 2013. Net income for the quarter ended March 31, 2013 was approximately $6.0 million, or approximately $0.08 per share, compared to a net loss of approximately $5.2 million, or approximately $0.09 per share, for the comparable pe...

Boston Scientific Subsidiaries Barred From Selling Multiple Drug-Eluting Stent Lines In Germany

A German court had previously barred Boston Scientific’s German subsidiary from selling drug-eluting stents affected by OrbusNeich’s patent suit and the new injunction prevents any Boston Scientific subsidiary from selling the devices in Germany.

Neptune Responds to Aker's Continued Attempts to Deflect Attention From Its Sustained Patent Infringement

LAVAL, Quebec, May 15, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) announces that the United States Patent and Trademark Office ("USPTO") recently issued a NON-FINAL Action Closing Prosecution (the "ACP") in a re-examination of Neptune's Patent No. 8,030,348 ("the '348 patent").  Aker BioMarine ("Aker"), in yet another clear attemp...

BioTime Appoints Franklin Berger to Board of Directors

BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger, CFA, 63, has been appointed to its Board of Directors. “We are pleased to welcome a recognized biotechnology industry expert of Franklin's caliber to BioTime's Board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Franklin adds to our Board a great deal of e...

Interleukin Genetics Reports First Quarter 2013 Financial Results

Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the first quarter ended March 31, 2013. Revenue for the quarter ended March 31, 2013 was $487,000, compared to $678,000 for the same period in 2012. The decrease is primarily attributable to decreased genetic testing revenue recognized from genetic tests...

LabStyle Innovations Reports First Quarter Results

Company makes significant strides in progressing Dario towards anticipated market launch, pending regulatory approvals LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of the Dario™ smartphone-based medical device and diabetes management system, today reported its financial and operational results for the three months ended March 31, 2013 an...

Monsanto Seed Patent Rights Not Exhausted After Sale

In a unanimous decision, the Supreme Court laid out that patent exhaustion does not permit a farmer to reproduce patented seeds through planting and harvesting without the patent holder’s permission. And….Boom Goes the Dynamite! (Bowman v. Monsan...

Can Merck's Pipeline Offset The Pain From Major Patent Expirations?

By Trefis: The pressure on Merck's (MRK) revenue growth is likely to continue in 2013, as the company battles multiple patent expiries and unfavorable currency movements. It is likely that there will be no respite in the near term, although the revenue declines for some of the major drugs will moderate in the latter half of 2013. Merck's best bet lies in its R&D to develop key drugs th...

Purdue Innovation Could Help People with Severe Hearing Loss

A Purdue University researcher's innovation may make it possible for people with severe hearing loss to hear high-frequency sounds. Joshua Alexander, an assistant professor in Purdue's Department of Speech, Language and Hearing Sciences, said conventional hearing aids do not help listeners with severe hearing lo

Depression market value to drop as pharma battles second cliff

As the second patent cliff for top-selling depression drugs approaches, the value of the depression market is set to decline from $5.6bn in 2012 to $4.7bn in 2016 in the seven major markets, new analysis indicates. However, according to.....

Nuvo Research granted U.S. Patent for treatment of allergic rhinitis and allergic asthma with WF10

MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the United States Patent Office has granted U.S. Patent # 8,435,568, relating to compositions and methods of using WF1...

Natural Alternatives International, Inc. Announces Fiscal 2013 Q3 and YTD Results

SAN MARCOS, Calif., May 14, 2013 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $178,000 or $0.03 per diluted share on net sales of $15.8 million for the quarter ended March 31, 2013.  Net sales for the three months ended March 31, 201...

Trovagene, Inc. Announces First Quarter 2013 Earnings

SAN DIEGO, May 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) First Quarter 2013 Financial Results For the first quarter ended March 31, 2013, Trovagene reported a net loss of $1.1 million,...

AbbVie Lose Their Chief Scientific Officer – What’s Happening to R&D?

Précis:  John Leonard, Chief Scientific Officer and Vice-President of AbbVie will leave the company in the coming months after twenty years of service, this is just the latest in a series of senior-l...

Bio Boy! Developing Markets to See Surge in Biosimilar Drug Growth

Précis:  The global biosimilar drug market for 2013 will see a 20% growth on last year’s figures to a whopping $2.44 billion, and a new survey indicates that this trend will continue to flourish fo...

Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, president, Primary Care and Women's Health, Merck, is scheduled to present at the Bank of America/Merrill Lynch 2013 Healthcare Conference in Las Vegas, Nevada, on May 15, 2013 at 9:20 a.m. PDT. Investors, analysts, members of the media and the general...

Lucintel Profiles Leaders in Generic Drugs Industry: Global Market Expected to Reach US $335.8 Billion in 2017

Lucintel profiles leaders in generic drugs industry: global market expected to reach US $335.8 Billion in 2017 Irving, TX (PRWEB) May 14, 2013 Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over th...

Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Rib-X Pharmaceuticals, Inc. has initiated a Phase 3 clinical trial of a Captisol-enabled™ intravenous (IV) formulation of delafloxacin for the first-line treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA. Under t...

Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day

ByPropThink: By Jake King Shares of Cubist Pharmaceuticals (CBST) have not significantly participated in the market rally, and relative to biotech peers, CBST has lagged on performance as well; the stock is up just 14% since last May compared to the AMEX Biotechnology index (BTK), up 33% in the same period. The key to CBST's stagnation is an ongoing patent challenge by generic drug manufacturer...

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed

By Scott Matusow:The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection, clinical research financial subsidization, and even tax breaks. Additionally, companies have greater success in gett...